Case Report
Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Pharmacol Ther. Jan 21, 2019; 10(1): 29-34
Published online Jan 21, 2019. doi: 10.4292/wjgpt.v10.i1.29
Ipilimumab and Nivolumab induced steroid-refractory colitis treated with infliximab: A case report
Ammar B Nassri, Valery Muenyi, Ahmad AlKhasawneh, Bruno De Souza Ribeiro, James S Scolapio, Miguel Malespin, Silvio W de Melo Jr
Ammar B Nassri, Valery Muenyi, Bruno De Souza Ribeiro, James S Scolapio, Miguel Malespin, Division of Gastroenterology and Hepatology, Department of Medicine, University of Florida at Jacksonville, Jacksonville, FL 32207, United States
Ahmad AlKhasawneh, Department of Pathology and Laboratory Medicine, University of Florida at Jacksonville, Jacksonville, FL 32209, United States
Silvio W de Melo Jr, Division of Gastroenterology, Oregon Health and Science University, Portland, OR 97239, United States
Author contributions: All Authors contributed to the manuscript. Nassri A is the article guarantor.
Informed consent statement: Written consent from the patient was obtained.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Ammar B Nassri, MD, Academic Fellow, Division of Gastroenterology and Hepatology, Department of Medicine, University of Florida at Jacksonville, 4555 Emerson St #300, Jacksonville, FL 32207, United States. anassri@gmail.com
Telephone: +1-904-6330797
Received: October 19, 2018
Peer-review started: October 19, 2018
First decision: November 15, 2018
Revised: December 6, 2018
Accepted: January 9, 2019
Article in press: January 9, 2019
Published online: January 21, 2019
Processing time: 94 Days and 17.6 Hours
Core Tip

Core tip: A variety of immune-modulating drugs are becoming increasingly used for various cancers. Despite increasing indications and improved efficacy, they are often associated with a wide variety of immune mediated adverse events. We report the first case of metastatic renal cell cancer treated with the anti-CTLA-4 monoclonal antibody Ipilimumab and the immune checkpoint inhibitor Nivolumab to develop severe steroid-refractory colitis, and describe its resolution after treatment with Infliximab.